Clinically important drug-drug interactions in primary care

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 4, 2012, Pages 426-430

  Dhabali, A A H ^a   Awang, R ^a   Zyoud, S H ^a  

^a SCHOOL OF PHYSICS   (Malaysia)

Author keywords

drug drug interactions; Malaysia; prevalence; primary care

Indexed keywords

DIGOXIN; DILTIAZEM; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; WARFARIN;

ARTICLE; DRUG POTENCY; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; HUMAN; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; TREND STUDY;

AGE FACTORS; AGED; DATABASES, FACTUAL; DRUG INTERACTIONS; HUMANS; MALAYSIA; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84863494506     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01314.x     Document Type: Article

References (33)

1. Astrand B, Astrand E, Antonov K, Petersson G., Detection of potential drug interactions-a model for a national pharmacy register. Eur J Clin Pharmacol, 2006; 62: 749-756. (Pubitemid 44289506)
2. van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P, Brouwers JR., Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf, 2005; 28: 1131-1139. (Pubitemid 41776003)
3. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA,. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA, 2003; 289: 1652-1658. (Pubitemid 37430270)
4. Peyriere H, Cassan S, Floutard E, Riviere S, Blayac J-P, Hillaire-Buys D, et al. Adverse drug events associated with hospital admission. Ann Pharmacother, 2003; 37: 5-11. (Pubitemid 36068590)
5. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH,. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf, 2007; 16: 641-651. (Pubitemid 47039530)
6. Brvar M, Fokter N, Bunc M, Mozina M,. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol, 2009; 9: 8.
7. Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, Good CB,. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm, 2003; 9: 513-522.
8. Bjerrum L, Andersen M, Petersen G, Kragstrup J., Exposure to potential drug interactions in primary health care. Scand J Prim Health Care, 2003; 21: 153-158. (Pubitemid 37174004)
9. Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V,. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther, 2005; 30: 13-20. (Pubitemid 41602088)
10. Gagne JJ, Maio V, Rabinowitz C,. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther, 2008; 33: 141-151. (Pubitemid 351341403)
11. Dhabali AA, Awang R,. A medication-estimated health status measure for predicting primary care visits: the Long-Term Therapeutic Groups Index. Health Policy Plan, 2010; 25: 162-169.
12. Bailie GR, Johnson CA, Mason NA, Peter WLS,. MedFacts pocket guide of drug interactions. Nephrology Pharmacy Associates Inc.: Verona, WI, USA, 2004.
13. Ament PW, Bertolino JG, Liszewski JL,. Clinically significant drug interactions. Am Fam Physician, 2000; 61: 1745-1754. (Pubitemid 30193572)
14. Barranco VP,. Update on clinically significant drug interactions in dermatology. J Am Acad Dermatol, 2006; 54: 676-684.
15. Tanaka E, Hisawa S,. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther, 1999; 24: 7-16. (Pubitemid 29171674)
16. Tanaka E,. Clinically significant pharmacokinetic drug interactions with benzodiazepines. J Clin Pharm Ther, 1999; 24: 347-355. (Pubitemid 29520784)
17. Eadie MJ,. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs, 2001; 15: 105-118. (Pubitemid 32195105)
18. Solberg LI, Hurley JS, Roberts MH, et al. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. Am J Manag Care, 2004; 10: 753-759. (Pubitemid 39518521)
19. Koda-Kimble MA,. Applied therapeutics: the clinical use of drugs. Philadelphia, PA: Lippincott Williams & Wilkins, 2004.
20. Dipiro J, Talbert RL, Talbert R, Yee G, Matzke G, Wells B, Posey LM,. Pharmacotherapy: a pathophysiologic approach. New York, NY: The McGraw-Hill Companies, 2005.
21. Aronson JK,. Meyler's side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. Amsterdam: Elsevier Science, 2006.
22. Don E., American Hospital Formulary Services. Bethesda, Maryland: American Society of Health-System Pharmacists, 2004.
23. Anderson PO,. Handbook of clinical drug data. New York: McGraw-Hill Medical Publishing, 2001.
24. Mozayani A, Raymon LP,. Handbook of drug interactions: a clinical and forensic guide. Totowa NJ: Humana Press Inc., 2004.
25. Lafata JE, Schultz L, Simpkins J, Chan KA, Horn JR, Kaatz S, et al. Potential drug-drug interactions in the outpatient setting. Med Care, 2006; 44: 534-541. (Pubitemid 44284293)
26. Dallenbach MF, Bovier PA, Desmeules J,. Detecting drug interactions using personal digital assistants in an out-patient clinic. QJM, 2007; 100: 691-697. (Pubitemid 350054273)
27. Zhan C, Correa-de-Araujo R, Bierman AS, Sangl J, Miller MR, Wickizer SW, Stryer D,. Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc, 2005; 53: 262-267. (Pubitemid 41632552)
28. Aparasu R, Baer R, Aparasu A,. Clinically important potential drug-drug interactions in outpatient settings. Res Social Adm Pharm, 2007; 3: 426-437.
29. Hazlet TK, Lee TA, Hansten PD, Horn JR,. Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash), 2001; 41: 200-204.
30. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB,. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc, 2004; 44: 136-141.
31. Cruciol-Souza JM, Thomson JC,. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci, 2006; 9: 427-433. (Pubitemid 46630111)
32. Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm, 2005; 62: 1983-1991. (Pubitemid 41416234)
33. Doubova Dubova SV, Reyes-Morales H, Torres-Arreola Ldel P, Suárez-Ortega M,. Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res, 2007; 7: 147.